18mth Treatment w/ PF-04494700 (TTP488) w/ Mod Alzheimer

ID Number 08-0194

Principal Investigator(s)
Mary Sano

Department(s) or Division(s)

The purpose of this study is to assess whether the use of the medication PF-04494700 is able to change the rate of memory loss in subjects with Alzheimer’s disease (AD). We will also be studying the effect of PF-04494700 on biomarkers. A biomarker is a brain scan or test that can be used to measure the progress of disease or the effects of treatment. Patients may qualify for participation in this study if they are at least 50 years old and have Alzheimer’s disease. Laboratory studies suggest that PF-04494700 might be helpful in the treatment of Alzheimer’s disease. Ten-week studies in participants diagnosed with Alzheimer’s disease have shown the medication to be safe and well tolerated in doses planned for the current research study. We do not know yet whether the use of PF-04494700 can change the course of Alzheimer’s disease, and the U.S. Food and Drug Administration (FDA) has not approved PF-04494700 for the treatment of Alzheimer’s disease.

Contact Information
Andrew Vigario
(212) 241-5692

Recruiting Patients: No